Logo Logo
Hilfe
Hilfe
Switch Language to English

Chatterjee, Madhurima; Özdemir, Selcuk; Fritz, Christian; Möbius, Wiebke ORCID logoORCID: https://orcid.org/0000-0002-2902-7165; Kleineidam, Luca; Mandelkow, Eckhard ORCID logoORCID: https://orcid.org/0000-0003-4655-4829; Biernat, Jacek; Doğdu, Cem; Peters, Oliver; Cosma, Nicoleta Carmen ORCID logoORCID: https://orcid.org/0000-0002-2656-8046; Wang, Xiao; Schneider, Luisa-Sophia; Priller, Josef ORCID logoORCID: https://orcid.org/0000-0001-7596-0979; Spruth, Eike; Kühn, Andrea A. ORCID logoORCID: https://orcid.org/0000-0002-4134-9060; Krause, Patricia; Klockgether, Thomas; Vogt, Ina R.; Kimmich, Okka; Spottke, Annika; Hoffmann, Daniel C.; Fliessbach, Klaus; Miklitz, Carolin; McCormick, Cornelia; Weydt, Patrick; Falkenburger, Björn; Brandt, Moritz; Guenther, René; Dinter, Elisabeth; Wiltfang, Jens; Hansen, Niels; Bähr, Mathias; Zerr, Inga; Flöel, Agnes; Nestor, Peter J.; Düzel, Emrah; Glanz, Wenzel; Incesoy, Enise; Bürger, Katharina; Janowitz, Daniel; Perneczky, Robert ORCID logoORCID: https://orcid.org/0000-0003-1981-7435; Rauchmann, Boris S.; Hopfner, Franziska ORCID logoORCID: https://orcid.org/0000-0001-6524-0281; Wagemann, Olivia; Levin, Johannes ORCID logoORCID: https://orcid.org/0000-0001-5092-4306; Teipel, Stefan; Kilimann, Ingo; Goerss, Doreen; Prudlo, Johannes; Gasser, Thomas; Brockmann, Kathrin ORCID logoORCID: https://orcid.org/0000-0002-7515-8596; Mengel, David; Zimmermann, Milan; Synofzik, Matthis; Wilke, Carlo; Selma-González, Judit; Turon-Sans, Janina; Santos-Santos, Miguel Angel; Alcolea, Daniel ORCID logoORCID: https://orcid.org/0000-0002-3819-3245; Rubio-Guerra, Sara ORCID logoORCID: https://orcid.org/0000-0001-7652-8029; Fortea, Juan ORCID logoORCID: https://orcid.org/0000-0002-1340-638X; Carbayo, Álvaro ORCID logoORCID: https://orcid.org/0000-0001-9282-8603; Lleó, Alberto ORCID logoORCID: https://orcid.org/0000-0002-2568-5478; Rojas-García, Ricardo; Illán-Gala, Ignacio; Wagner, Michael; Frommann, Ingo ORCID logoORCID: https://orcid.org/0000-0002-7244-2014; Roeske, Sandra ORCID logoORCID: https://orcid.org/0000-0002-8262-4356; Bertram, Lucas ORCID logoORCID: https://orcid.org/0009-0005-3594-6925; Heneka, Michael T. ORCID logoORCID: https://orcid.org/0000-0003-4996-1630; Brosseron, Frederic; Ramirez, Alfredo ORCID logoORCID: https://orcid.org/0000-0003-4991-763X; Schmid, Matthias; Beschorner, Rudi ORCID logoORCID: https://orcid.org/0000-0003-1109-915X; Halle, Annett; Herms, Jochen; Neumann, Manuela; Barthélemy, Nicolas R.; Bateman, Randall J. ORCID logoORCID: https://orcid.org/0000-0002-7729-1702; Rizzu, Patrizia; Heutink, Peter; Dols-Icardo, Oriol ORCID logoORCID: https://orcid.org/0000-0003-2656-8748; Höglinger, Günter ORCID logoORCID: https://orcid.org/0000-0001-7587-6187; Hermann, Andreas ORCID logoORCID: https://orcid.org/0000-0002-7364-7791 und Schneider, Anja ORCID logoORCID: https://orcid.org/0000-0001-9540-8700 (2024): Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. In: Nature Medicine, Bd. 30, Nr. 6: S. 1771-1783 [PDF, 12MB]

Abstract

Minimally invasive biomarkers are urgently needed to detect molecular pathology in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Here, we show that plasma extracellular vesicles (EVs) contain quantifiable amounts of TDP-43 and full-length tau, which allow the quantification of 3-repeat (3R) and 4-repeat (4R) tau isoforms. Plasma EV TDP-43 levels and EV 3R/4R tau ratios were determined in a cohort of 704 patients, including 37 genetically and 31 neuropathologically proven cases. Diagnostic groups comprised patients with TDP-43 proteinopathy ALS, 4R tauopathy progressive supranuclear palsy, behavior variant FTD (bvFTD) as a group with either tau or TDP-43 pathology, and healthy controls. EV tau ratios were low in progressive supranuclear palsy and high in bvFTD with tau pathology. EV TDP-43 levels were high in ALS and in bvFTD with TDP-43 pathology. Both markers discriminated between the diagnostic groups with area under the curve values >0.9, and between TDP-43 and tau pathology in bvFTD. Both markers strongly correlated with neurodegeneration, and clinical and neuropsychological markers of disease severity. Findings were replicated in an independent validation cohort of 292 patients including 34 genetically confirmed cases. Taken together, the combination of EV TDP-43 levels and EV 3R/4R tau ratios may aid the molecular diagnosis of FTD, FTD spectrum disorders and ALS, providing a potential biomarker to monitor disease progression and target engagement in clinical trials.

Dokument bearbeiten Dokument bearbeiten